Isodiol International Inc. is increasing the size of its previously announced private placement from $10 million to $18 million. The company engaged Clarus Securities Inc. as the financial advisor for the offering.
Anson Funds, a privately held alternative asset management company, is the primary investor for the additional investments. The offering is expected to close on or about May 11, subject to customary closing conditions. Isodiol will use the proceeds from the offering to fund its expansion into China and the United Kingdom (UK).
Isodiol’s Expansion into China and the UK
Isodiol is developing a state-of-the-art processing facility in Yunnan, China. The new facility will extract cannabinoids and terpenes from certified organic hemp. It will process over 15 metric tons of hemp biomass every day.
Isodiol has also acquired 100% of BSPG Laboratories in the UK. It will have complete access to BSPG’s exclusive technologies and processes to extract hemp. BSPG also owns an operating facility that refines the cannabidiol (CBD) molecule to a purity of 99.5% – which means it is highly bioactive and does not contain the high-inducing ingredient called tetrahydrocannabinol (THC).
Moreover, Isodiol has purchased strategic assets in the UK and China. It has expanded its international management team to handle the changes efficiently.
These developments show that Isodiol is actively working on its goal to enter international markets and increase revenue. The company foresees a bright future for CBD products due to increasing global demand.
About Isodiol International Inc.
Isodiol is a market leader in pharmaceutical-grade phytochemical compounds and an industry leader in the development of CBD consumer products. It is one of the pioneers in the commercialization of 99%+ pure cannabinoids, microencapsulation, and nanotechnology.
The company manufactures the highest-quality consumable and topical products for skin care and pain management. Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs and the expansion of its phytoceutical portfolio. Besides this, the company plans to aggressively expand into international markets like Latin America, Asia, and Europe.